Abstract
CD38 is a type II transmembrane glycoprotein that is highly expressed in multiple myeloma and is a promising target for immunotherapy. Daratumumab is a human monoclonal antibody that has potent anti-multiple myeloma activity both as monotherapy and in combination with other multiple myeloma treatments, and has breakthrough designation on this basis.
©2015 American Association for Cancer Research.
Publication types
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
ADP-ribosyl Cyclase 1 / antagonists & inhibitors*
-
ADP-ribosyl Cyclase 1 / metabolism*
-
Animals
-
Bortezomib / pharmacology*
-
Female
-
Humans
-
Lenalidomide
-
Male
-
Multiple Myeloma / immunology*
-
Multiple Myeloma / metabolism*
-
Thalidomide / analogs & derivatives*
-
Thalidomide / pharmacology
Substances
-
Thalidomide
-
Bortezomib
-
ADP-ribosyl Cyclase 1
-
Lenalidomide